Showing 6561-6570 of 8885 results for "".
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Glenmark Pharmaceuticals Enters US Branded Dermatology Segmenthttps://practicaldermatology.com/news/glenmark-pharmaceuticals-enters-us-branded-dermatology-segment/2457537/Glenmark Pharmaceuticals is entering into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA. This represents an imp
- Rio Professor Develops Sunscreen for Hairhttps://practicaldermatology.com/news/rio-professor-develops-sunscreen-for-hair/2457538/A Rio professor and her team of students have developed the first national product capable of protecting hair from sun radiation. According to Ana Percebom, of the Scientific Technical Center of University PUC in Rio, none of the products currently sold have substances that actually block
- AD, Suicidal Thoughts and Attempts Linkedhttps://practicaldermatology.com/news/ad-suicidal-thoughts-and-attempts-linked/2457543/Patients with eczema may be more likely to have suicidal thoughts and attempts compared to their counterparts without eczema, according to a new study in JAMA Dermatology. Res
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://practicaldermatology.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2457546/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Low 3% Keloid Recurrence Found in Multicenter Case Series of Patients Treated with SRThttps://practicaldermatology.com/news/low-3-keloid-recurrence-found-in-multicenter-case-series-of-patients-treated-with-srt/2457488/Sensus Healthcare, Inc., a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), shared positive results of a multicenter case series of patients treated with the SRT-100 following
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Crown Laboratories Acquires Select Healthcare Brands from GlaxoSmithKlinehttps://practicaldermatology.com/news/crown-laboratories-acquires-select-healthcare-brands-from-glaxosmithkline/2457492/Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, De